A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.

Michael B. Livingston,Megan Jagosky,Myra M. Robinson,William A. Ahrens,Jennifer H. Benbow,Carol J. Farhangfar,David M. Foureau,Deirdre Maxwell,Emily Baldrige,Nury Steuerwald,Colin J. Anderson,Joshua C. Patt,Jeffrey S. Kneisl,Edward S. Kim

A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.

2020

Michael B. Livingston
Megan Jagosky
Myra M. Robinson
William A. Ahrens
Jennifer H. Benbow
Carol J. Farhangfar
David M. Foureau
Deirdre Maxwell
Emily Baldrige
Nury Steuerwald
Colin J. Anderson
Joshua C. Patt
Jeffrey S. Kneisl
Edward S. Kim

11519Background: Doxorubicin has been the traditional standard therapy for treatment of advanced soft tissue sarcoma (STS). The addition of cytotoxic agents leads to increased toxicity with minimal...

Keywords:

Oncology
safety tolerability
Doxorubicin
Internal medicine
in patient
Pathology
Pembrolizumab
Soft tissue sarcoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations